Guinea pigs vaccinated with bacille Calmette-Guérin (BCG) and unvaccinated guinea pigs were challenged by the respiratory route six weeks or six months after vaccination and sacrificed at various intervals after challenge. The six lobes of the lung were cultured separately, and the percentage of culture-positive lobes was calculated, as well as the log10 number of virulent bacilli recovered. The latter was subjected to an analysis of variance, which compared the fate of bacilli in the four largest lobes with the fate of those in the two smallest lobes. The results indicated no difference between the six-week and six-month intervals between vaccination and challenge. In the longer intervals between challenge and sacrifice, small numbers of secondary lesions could be seen on the lobes of the BCG-vaccinated animals. It was concluded that vaccination with BCG retarded the onset and/or reduced the extent of hematogenous dissemination of virulent mycobacteria to the lungs.

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/136.3.439DOI Listing

Publication Analysis

Top Keywords

bacille calmette-guérin
8
onset and/or
8
extent hematogenous
8
hematogenous dissemination
8
dissemination virulent
8
guinea pigs
8
intervals challenge
8
lobes
5
host-parasite relationships
4
relationships experimental
4

Similar Publications

Tuberculosis vaccines and therapeutic drug: challenges and future directions.

Mol Biomed

January 2025

Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 17#Heishanhu Road, Haidian District, Beijing, 100091, China.

Tuberculosis (TB) remains a prominent global health challenge, with the World Health Organization documenting over 1 million annual fatalities. Despite the deployment of the Bacille Calmette-Guérin (BCG) vaccine and available therapeutic agents, the escalation of drug-resistant Mycobacterium tuberculosis strains underscores the pressing need for more efficacious vaccines and treatments. This review meticulously maps out the contemporary landscape of TB vaccine development, with a focus on antigen identification, clinical trial progress, and the obstacles and future trajectories in vaccine research.

View Article and Find Full Text PDF

Background: Accurate diagnosis of tuberculosis (TB) in children continues to be challenging, primarily due to the low bacterial load characteristic of the disease and the obstacles in collecting sputum samples. Furthermore, detecting cases of latent Mycobacterium tuberculosis (M.tb) infection (LTBI) that have a high risk of progressing to active TB disease remains a significant diagnostic hurdle.

View Article and Find Full Text PDF

Tuberculosis (TB) remains a highly lethal infectious disease. The primary preventive measure is Bacille Calmette-Guérin (BCG), a live attenuated vaccine. However, the current intradermal vaccination method with 10-dose vials faces challenges such as inadequate infant injection, inaccurate dispensing, and unstable storage.

View Article and Find Full Text PDF

After more than a century since its initial development, Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB). Subunit boosters are considered a viable strategy to enhance BCG efficacy, which often wanes in adolescence. While many studies on booster subunit vaccines have concentrated on recombinant proteins, here we developed a novel modular peptide-based subunit vaccine platform that is flexible, cold-chain independent and customizable to diverse circumstances and populations.

View Article and Find Full Text PDF

Purpose: Tuberculosis (TB) remains a significant public health concern globally. Bacille Calmette-Guérin (BCG) vaccination is widely used, but scar formation post-vaccination is not universal, which raises concerns about its efficacy. The Mantoux test is used to assess the immune response following BCG vaccination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!